BSIM Therapeutics
Coimbra
About BSIM Therapeutics
BSIM’s mission is to deliver quality drug candidates with high capital efficiency against transthyretin-mediated amyloidosis, including clinical manifestations and related pathologies that represent important and unmet medical needs. Our products are directed to a group of rare, hereditary and fatal pathologies commonly addressed to as Transthyretin Amyloidoses (hATTR). We are developing drug candidates that fit within distinct target-product profiles for the treatment of a broader range of hATTR manifestations, including central nervous system symptoms (e.g. seizures, stroke-like events, progressive dementia) and oculopathy (e.g. vitreous opacities, glaucoma).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $2.9M
- Funding stage: Seed
- Last round: Seed (Feb 2017)
- Website: bsimtx.com
- Phone: +351 239 405 201
Industries & Categories
Biotechnology, Chemical Engineering, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/bsim-therapeutics-195665 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.